Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.

NCT Number	NCT06288360
Lead Sponsor	Tongji Hospital Collaborators: Southwest Hospital, China, Women's Hospital School Of Medicine Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Gansu Provincial Maternal and Child Health Care Hospital, Beijing Friendship Hospital, Tianjin Medical University General Hospital, Xiangya Hospital of Central South University, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhejiang Cancer Hospital, Shengjing Hospital, Qilu Hospital of Shandong University, Cancer Hospital of Guangxi Medical University
Conditions	Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
Enrollment	40 participants
Start Date	2024-09-12
Primary Completion	2025-12-31 (estimated)
Study Completion	2030-12-12 (estimated)
Updated on ClinicalTrials.gov	2025-03-20